West Pharmaceutical Services, Inc. Q2 2025 Earnings Recap

WST Q2 2025 July 25, 2025

Get alerts when WST reports next quarter

West Pharmaceutical Services reported strong Q2 2025 results, with net sales increasing 9.2%, driven primarily by robust growth in HVP components and GLP-1 elastomer products.

Earnings Per Share Beat

$1.84 vs $1.51 est.

+21.9% surprise

Revenue Beat

766200000 vs 726090818 est.

+5.5% surprise

See WST alongside your other holdings

Add to your portfolio — free

Key Takeaways

Net sales rose 9.2%, with 6.8% organic growth, reflecting strong customer demand and normalization of ordering patterns.
Proprietary Products segment grew 8.4% organically, propelled by an 11.3% increase in HVP components tied to GLP-1 elastomer demand.
Strong performance in HVP Delivery Devices segment saw a revenue increase of 30%, primarily due to Daikyo Crystal Zenith systems.
Full-year 2025 guidance for organic revenue and adjusted EPS has been increased based on Q2 performance and favorable FX trends.
West is proactively addressing capacity constraints in Europe with hiring and training initiatives to enhance production efficiency.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit WST on AllInvestView.

Next Q3 2025